Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PPM1B | O75688 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135813 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A3SLC6A4ALDH1A1PRCP | |
| SCHEMBL3164291 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A3SLC6A4ALDH1A1PRCP | |
| Hydrochloric Acid SCHEMBL6733273 | 0.98 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4ALDH1A1PRCP | |
| SCHEMBL5429881 | 0.98 | ALDH1A1 (0.44) | SLC6A2SLC6A3SLC6A4ALDH1A1PRCP | |
| Hydrochloric Acid SCHEMBL6954164 | 0.98 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4ALDH1A1PRCP | |
| SCHEMBL9438838 | 0.98 | ALDH1A1 (0.44) | SLC6A2SLC6A3SLC6A4ALDH1A1PRCP | |
| SCHEMBL9438970 | 0.98 | ALDH1A1 (0.44) | SLC6A2SLC6A3SLC6A4ALDH1A1PRCP | |
| Hydrochloric Acid SCHEMBL1282288 | 0.98 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4ALDH1A1PRCP | |
| SCHEMBL9439436 | 0.98 | ALDH1A1 (0.44) | SLC6A2SLC6A3SLC6A4ALDH1A1PRCP | |
| Oxalic Acid SCHEMBL29060702 | 0.95 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4ALDH1A1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326732-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2023034346-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-2831069-B1 | ISOXAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-07-12 | — | — | EP | disclosed |
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2013007371-A2 | KINETIC RESOLUTION OF CHIRAL AMINES | ETH ZURICH (CH) | 2013-01-17 | — | — | WO | disclosed |
| US-20120130076-A1 | Synthetic Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8106191-B2 | Compounds based on N- acyl-pipecolyl and N-acyl-prolyl ligand moieties for multimerizing chimeric proteins containing immunophilin-derived domains | ARIAD PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110152234-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-7956084-B2 | Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
| EP-0820451-B1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK AS (DK) | 2003-01-15 | — | — | EP | disclosed |
| CN-1315951-A | FKBP inhibitors | PFIZER LTD (US) | 2001-10-03 | — | — | CN | disclosed |
| US-6239148-B1 | TREATMENT OF PAINFUL, HYPERALGESIC AND/OR INFLAMMATORY CONDITIONS IN WHICH C-FIBERS PLAY A ROLE BY ELICITING NEUROGENIC PAIN, INSULIN RESISTANCE IN DIABETES MELLITUS OR AGING, INHIBIT INSULIN ANTAGONIZING PEPTIDE, | NOVO NORDISK A/S (DK) | 2001-05-29 | — | — | US | disclosed |
| US-6166009-A | N-substituted azaheterocyclic carboxylic acids and esters thereof | NOVO NORDISK A/S (DK) | 2000-12-26 | — | — | US | disclosed |
| US-6110913-A | ANTIINFLAMMATORY AGENTS, ANALGESICS | NOVO NORDISK A/S (DK) | 2000-08-29 | — | — | US | disclosed |
| US-6071901-A | TREATING PAIN, HYPERALGESIA AND/OR INFLAMMATORY CONDITIONS IN WHICH C-FIBERS PLAY A PATHOPHYSIOLOGICAL ROLE; INHIBITION OF NEUROGENIC INFLAMMATION INVOLVING THE RELEASE OF NEURO-PEPTIDE FROM PERIPHERAL AND CENTRAL ENDINGS OF SENSORY NERVES | NOVO NORDISK A/S (DK) | 2000-06-06 | — | — | US | disclosed |
| US-5874428-A | A DRUG TREATING DIABETIC NEUROPATHY, MIGRAINE, NEUROGENIC INFLAMMATION OR RHEUMATOID ARTHRITIS | NOVO NORDISK ALS (DK) | 1999-02-23 | — | — | US | disclosed |
| EP-0820451-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996031498-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326732-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | POLRMT, TFAM, POLM | SLC6A2 4048/4885SLC6A3 4538/4885SLC6A4 4127/4885 |
| US-20120130076-A1 | Synthetic Multimerizing Agents | FKBP1B, FKBP2, FKBP14 | SLC6A2 4347/4885SLC6A3 4806/4885SLC6A4 4058/4885 |
| US-20110152234-A1 | Novel Compounds | CNR1, ABCG2, CNR2 | SLC6A2 2320/4885SLC6A3 1646/4885SLC6A4 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.